Certain public-reported immune-mediated adverse events for PD-1 inhibitors in melanoma occur at higher rates than in clinical trials.
N GuptaC CullisonA MallyL XiangS T HillM G BeveridgePublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)